Racecadotril + Racecadotril + Racecadotril + Racecadotril

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diarrhea

Conditions

Diarrhea

Trial Timeline

Dec 1, 2011 → Dec 1, 2011

NCT ID

NCT01476683

About Racecadotril + Racecadotril + Racecadotril + Racecadotril

Racecadotril + Racecadotril + Racecadotril + Racecadotril is a phase 1 stage product being developed by Johnson & Johnson for Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT01476683. Target conditions include Diarrhea.

What happened to similar drugs?

8 of 20 similar drugs in Diarrhea were approved

Approved (8) Terminated (4) Active (10)

🔄YM060 + PlaceboAstellas PharmaPhase 3

🔄Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3

🔄YM060Astellas PharmaPhase 3

✅loperamide-simethicone + matching placeboJohnson & JohnsonApproved

✅Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsulesJohnson & JohnsonApproved

🔄fidaxomicin + PlaceboMerckPhase 3

✅RV5 (Pentavalent Rotavirus Vaccine)MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01476683	Phase 1	Completed	Dec 1, 2011	Dec 1, 2011	Diarrhea

Competing Products

20 competing products in Diarrhea

See all competitors

Product	Company	Stage	Hype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2	Dr. Reddy's Laboratories	Phase 2	32
YM060 + Placebo	Astellas Pharma	Phase 3	40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	40
YM060	Astellas Pharma	Phase 3	40
Ramosetron	Astellas Pharma	Pre-clinical	26
Racecadotril Film-Coated Tablet (FCT) + Racecadotril Capsule	Johnson & Johnson	Phase 1	29
loperamide-simethicone + matching placebo	Johnson & Johnson	Approved	43
Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules	Johnson & Johnson	Approved	43
fidaxomicin + Placebo	Merck	Phase 3	40
Surotomycin + Placebo	Merck	Phase 1	29
Surotomycin + Placebo	Merck	Phase 1	29
OPT-80	Merck	Phase 2	35
fidaxomicin	Merck	Phase 2	35
RV5 (Pentavalent Rotavirus Vaccine)	Merck	Approved	43
LJN452 + Placebo to LJN452	Novartis	Phase 2	35
Octreotide Long Acting Release	Novartis	Phase 3	40
DNK333 + Placebo	Novartis	Phase 2	35
Probiotic Supplement	Roche	Pre-clinical	26
Etrasimod + Placebo + Corticosteroids	Pfizer	Phase 2	27
Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine	Pfizer	Phase 3	32